Kimball Electronics has reported its financial performance for the fourth quarter of fiscal year 2026, alongside its outlook for fiscal year 2027. The company highlighted a strategic transition towards organic growth, primarily driven by its expanding medical segment, significantly bolstered by the recent acquisition of Helvoet Polymer Technologies. Despite a slight year-over-year dip in net sales for Q4, the company demonstrated sequential growth and a robust financial position, marked by reduced debt and strong cash generation. The executive team outlined plans for continued investment in growth initiatives, balanced capital allocation, and a focus on integrating new assets to unlock future revenue synergies.
The company's financial health and strategic direction are strongly influenced by its ability to navigate market fluctuations across its diverse segments while investing in high-growth areas. The proactive management of its balance sheet, coupled with a clear vision for expanding its medical footprint, positions Kimball Electronics for anticipated growth in the upcoming fiscal year. Key areas of focus include leveraging the Helvoet acquisition for medical co-development work and scaling up production at its new Indianapolis facility, signaling a commitment to innovation and market leadership in the Contract Development and Manufacturing Organization (CDMO) space.
Fiscal 2026 Performance and Strategic Market Shifts
For the fourth quarter of fiscal 2026, Kimball Electronics achieved net sales of $371.6 million. This figure represents a modest 2% decline compared to the same period in the prior year but marks a 5% sequential increase from the third quarter. The Medical segment emerged as a significant driver of growth, reporting $108.8 million in sales, a 1% year-over-year increase, and now accounting for 29% of the company's total revenue. This growth was particularly strong in Asia and Europe, driven by demand in surgical devices, in vitro diagnostics, patient monitoring, and drug delivery systems. The Automotive sector, while experiencing a 3% decrease to $169.7 million due to lower electric vehicle demand, saw some stabilization from new steering and braking programs in Poland and Romania. Industrial sales, totaling $93.1 million, declined by 5%, primarily from reduced demand for HVAC systems in North America, though partially mitigated by increased smart meter sales in Europe. Adjusted operating income for the quarter stood at $18.1 million, or 4.9% of net sales, and gross margin improved to 8.9% due to a favorable product mix. The company also reported robust cash generation from operations, totaling $42.4 million, contributing to a significant reduction in total debt to $116.6 million, its lowest in over four years.
Kimball Electronics concluded fiscal year 2026 with total net sales of $1.431 billion. The Medical segment's growth exceeded 10% after adjusting for prior-year consigned inventory sales, underscoring its pivotal role in the company's future strategy. Adjusted operating income for the full year reached $65.7 million, equating to 4.6% of net sales, while operating cash flow was a healthy $72.3 million. The company strategically invested $51.7 million in capital expenditures, predominantly for leasehold improvements in its new Indianapolis medical facility and new programs in Europe. A key financial highlight was the improvement in cash conversion days to 82, the best in 17 quarters, reflecting enhanced efficiency in converting investments into cash flow. Share repurchases amounted to $2.1 million in Q4 and $11.9 million for the full fiscal year, with $24.4 million remaining in the authorized program. Despite a high effective tax rate of 67.8% in Q4 due to international dividend withholding matters, the company anticipates a normalization to the low 30s for fiscal 2027. The geographical distribution of sales in Q4 was notably balanced, with North America contributing 40%, and Asia and Europe each accounting for 30%, indicating a more globally diversified operational footprint.
Outlook for Fiscal Year 2027 and Growth Initiatives
Kimball Electronics projects a significant return to growth in fiscal year 2027, with anticipated net sales ranging from $1.535 billion to $1.560 billion, representing a 7% to 9% increase over fiscal 2026. This optimistic outlook is underpinned by an expected organic sales growth of 3% to 5%, with a substantial contribution of $60 million from the recently acquired Helvoet Polymer Technologies. The Medical segment is forecast to be the primary growth engine, with organic expansion predicted in the high single-digit to low double-digit range, aiming to exceed 35% of total company sales. The Industrial segment's growth is expected to align with the company average, while the Automotive segment is projected to remain largely stable. The integration of Helvoet, finalized on July 1, 2026, is progressing smoothly, with a strong focus on realizing top-line synergies and leveraging its operations in Tilburg and Pune. Customer engagement around the acquisition has been positive, indicating potential for new business opportunities. Additionally, the new medical CDMO facility in Indianapolis is on track, with production equipment installation underway and early production slated to commence by the end of the calendar year, followed by a full transition from the existing campus within 18 months.
The company's strategic vision for fiscal 2027 emphasizes robust capital allocation and continuous investment in its core business and strategic acquisitions. Adjusted operating income is estimated to be between 4.4% and 4.7% of net sales, reflecting the dilutive impact of the new Indianapolis facility's ramp-up being offset by the accretive benefits of the Helvoet acquisition. Capital expenditures are projected to be in the range of $50 million to $60 million, earmarked for ongoing facility enhancements and new program support. Kimball Electronics aims to maintain a strong balance sheet, targeting a leverage ratio between 1.5x and 2x EBITDA, ensuring sufficient liquidity for future strategic inorganic growth opportunities while also continuing its share repurchase program. The company's commitment to its full-service provider strategy in Kimball Solutions is further reinforced by the incorporation of the "D" in Medical CDMO, highlighting its co-development capabilities. Management remains vigilant about market challenges, such as potential working capital pressure from supply chain disruptions and increased customer demand for safety stocks, but remains confident in its ability to deliver profitable growth through diversified offerings and strategic investments.
